WO2022195212A1 - Inhibiteurs glycosidiques de levure - Google Patents
Inhibiteurs glycosidiques de levure Download PDFInfo
- Publication number
- WO2022195212A1 WO2022195212A1 PCT/FR2022/050459 FR2022050459W WO2022195212A1 WO 2022195212 A1 WO2022195212 A1 WO 2022195212A1 FR 2022050459 W FR2022050459 W FR 2022050459W WO 2022195212 A1 WO2022195212 A1 WO 2022195212A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- yeast
- cncm
- composition
- fraction
- glucans
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 158
- 239000003112 inhibitor Substances 0.000 title description 2
- 229930182470 glycoside Natural products 0.000 title 1
- 150000002338 glycosides Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 81
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 36
- 229920000057 Mannan Polymers 0.000 claims abstract description 36
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims abstract description 34
- 150000004676 glycans Chemical class 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 32
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 32
- 239000005017 polysaccharide Substances 0.000 claims abstract description 32
- 229920000310 Alpha glucan Polymers 0.000 claims abstract description 24
- 230000000968 intestinal effect Effects 0.000 claims abstract description 22
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 230000007170 pathology Effects 0.000 claims abstract description 15
- 230000002496 gastric effect Effects 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims abstract description 13
- 244000000010 microbial pathogen Species 0.000 claims abstract description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 147
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 70
- 230000001936 parietal effect Effects 0.000 claims description 41
- 241000588724 Escherichia coli Species 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 239000000284 extract Substances 0.000 abstract description 2
- 229920001503 Glucan Polymers 0.000 description 51
- 241000894006 Bacteria Species 0.000 description 40
- 239000000243 solution Substances 0.000 description 36
- 210000005253 yeast cell Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 23
- 239000008188 pellet Substances 0.000 description 21
- 238000005119 centrifugation Methods 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 210000003918 fraction a Anatomy 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 229920002527 Glycogen Polymers 0.000 description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 229940096919 glycogen Drugs 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000011533 pre-incubation Methods 0.000 description 10
- 210000002421 cell wall Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000009545 invasion Effects 0.000 description 9
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 4
- 241000588921 Enterobacteriaceae Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- 208000035404 Autolysis Diseases 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102100024023 Histone PARylation factor 1 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 108010075437 phosphopeptidomannan Proteins 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028043 self proteolysis Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 208000034309 Bacterial disease carrier Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008952 bacterial invasion Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108010005335 mannoproteins Proteins 0.000 description 2
- 150000002704 mannoses Chemical class 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 206010052813 Aerophagia Diseases 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 239000004128 Copper(II) sulphate Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001608234 Faecalibacterium Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 101001047783 Homo sapiens Histone PARylation factor 1 Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- XRKZVXDFKCVICZ-IJLUTSLNSA-N SCB1 Chemical compound CC(C)CCCC[C@@H](O)[C@H]1[C@H](CO)COC1=O XRKZVXDFKCVICZ-IJLUTSLNSA-N 0.000 description 1
- 241000235072 Saccharomyces bayanus Species 0.000 description 1
- 101100439280 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CLB1 gene Proteins 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000582914 Saccharomyces uvarum Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 108010004171 colibactin Proteins 0.000 description 1
- ZWKHDAZPVITMAI-ROUUACIJSA-N colibactin Chemical compound C[C@H]1CCC(=N1)C1=C(CC(=O)NCC(=O)c2csc(n2)C(=O)C(=O)c2csc(CNC(=O)CC3=C(C(=O)NC33CC3)C3=N[C@@H](C)CC3)n2)C2(CC2)NC1=O ZWKHDAZPVITMAI-ROUUACIJSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004699 copper complex Chemical class 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 201000000117 functional diarrhea Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 231100000446 genotoxin Toxicity 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 102000046810 human CEACAM6 Human genes 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001476 sodium potassium tartrate Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates to a process for obtaining a composition of parietal yeast polysaccharides and to its use for the treatment of gastrointestinal pathologies or for the preparation of food supplements aimed at improving intestinal comfort.
- microorganisms have already been described in the literature for their beneficial applications in humans on the digestive tract and for their nutritional interest, as described, for example, in WO 2006/021965. These microorganisms are then commonly designated by the term probiotic which corresponds to live microorganisms capable of providing the host with a health benefit when administered in adequate quantities (Joint FAO/WHO Expert Consultation Probiotics in food, FAO Food and nutrition paper Nr85, ISBN 92-5-105513 -0).
- Saccharomyces cerevisiae Saccharomyces cerevisiae
- yeasts for treating pathologies associated with enterobacteriaceae
- the prior application FR 2 928 652 teaches that the yeast strain S. cerevisiae (CNCM I-3856, ScProl) is of therapeutic and prophylactic interest for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms by limiting in particular colonization and / or the intestinal invasion of these microorganisms.
- the administration of this yeast leads to a decrease in enterobacteriaceae in the colon.
- yeast parietal glucans have thus been used to enhance or prime the immune response in humans and animals with normal or diminished immunological function (G. Hetland. Curr. Med. Chem. - Anti-infective Agents 2003, 2: 135; PJ Rice, BE Lockhart, LA Barker, EL Adams, HE Ensley, DL Williams. Int. Immunopharmacol. 2004, 33:829).
- Application WO 2009/103884 teaches more particularly that yeast parietal beta-glucans (in particular the CNCM I-3856 strain) limit intestinal inflammation.
- corticosteroids are used less and less. It is therefore essential on the one hand to develop and improve existing prophylactic treatments, making it possible to improve intestinal comfort in healthy subjects, and on the other hand to prevent the development of pathologies in subjects at risk and on the other hand to develop effective therapies that are better tolerated for patients suffering from gastrointestinal pathologies such as IBD.
- a composition of yeast polysaccharides comprising ⁇ -glucans and/or ⁇ -glucans and/or mannans is proposed, characterized in that the said yeast polysaccharides are extracted from yeast cell walls.
- ⁇ -glucans are ⁇ (1,6)-glucans.
- the composition further includes mannans and ⁇ -glucans.
- the present application proposes a composition comprising from 5 to 25%, in particular from 10 to 20%, of ⁇ -glucans; from 30 to 50%, in particular from 35 to 45%, of ⁇ -glucans (in particular from ⁇ 6-glucans; and from 30 to 55%, in particular from 40 to 50%, of mannans.
- the yeasts are chosen from yeasts of the genus Saccharomyces. They can thus be chosen from the group comprising the strains deposited with the National Collection of Microorganism Culture under the numbers CNCM I-3799, CNCM I-3856, CNCM I-4407, CNCM I-4563, CNCM 1-4812, CNCM I-4978, CNCM 1-5128, CNCM 1-5129, CNCM I-5268, and CNCM I-5269 and the strain deposited with the Collection of industrial yeasts DBVPG 6763.
- a process for obtaining a composition of yeast comprising: a) at least one step of fractionating (typically by hot incubation) of a parietal composition of yeast(s) and recovery (extraction) of an insoluble fraction (called “insoluble fraction a”); and b) at least one step of extracting a soluble fraction (called "soluble fraction b") from the insoluble fraction a), said fraction containing ⁇ -glucans (in particular ⁇ 6-glucans), preferably also mannans and generally ⁇ -glucans - this step typically comprises at least one step of incubating the soluble fraction a) in a weak acid solution, and recovering (extraction) of a soluble fraction ("soluble fraction b”).
- the method includes a preliminary step for obtaining an insoluble parietal fraction of yeast(s).
- the method preferably comprises a step a1) of incubating the insoluble fraction a) in a strong base solution, after which the fraction insoluble fraction (called insoluble fraction a1) is recovered.
- the fraction (or composition) incubated in the weak acid solution of step b) described above is then the “insoluble fraction a1”.
- the present disclosure also relates to a composition of yeast polysaccharides comprising ⁇ -glucans, mannans and ⁇ -glucans as described in the present application, in particular as obtained according to the process described here, for its use in the treatment and/or prevention of gastrointestinal pathologies.
- the present invention finally relates to a non-therapeutic use of a composition as defined in the present disclosure, and in particular obtained according to the process described here, for the preparation of a food composition intended to improve gastrointestinal comfort. intestinal and/or to improve and maintain the homeostasis of the intestinal microbiota.
- FIG. 1 Diagrams illustrating the different protocols implemented.
- the top diagram (A) illustrates the extraction of the different fractions of yeast polysaccharides from whole yeast or yeast cell walls.
- the bottom diagram (B) corresponds to the process of the invention in which the various yeast polysaccharide fractions are extracted from yeast cell walls.
- Fig. 2 Diagram of the preincubation protocol on T84 and Caco-2 intestinal epithelial cells.
- the fractions extracted from yeasts are first incubated with the AIEC bacteria then added to the cultures of intestinal epithelial cells organized in epithelium.
- the residual adhesion level of the AIEC LF82 bacterial strain is then estimated for decreasing concentrations of yeast fractions (1; 0.5; 0.25; 0.1 mg/mL).
- FIG. 3 Residual adhesion levels (percentages) of the AIEC LF82 strain to T84 cells (preincubation protocol) in the presence of "soluble fraction a” (also called Fehling mannans because of the phospho-peptidomannan extraction protocol) (fraction 1, also called soluble fraction a”), or “soluble fraction b” (fraction 3) obtained from the whole yeast strain CNCM I-3856 (means ⁇ wk; ** : p ⁇ 0.01, * ** : p ⁇ 0.001, t-test).
- soluble fraction a also called Fehling mannans because of the phospho-peptidomannan extraction protocol
- FIG. 6 Residual adhesion levels (percentages) of AIEC LF82 strain to T84 cells (preincubation protocol) in the presence of "soluble fraction b" (fraction 3) obtained from CNCM I-3856 yeast cell walls or from leave of CNCM I-5268 yeast cell walls (means ⁇ sem; * :p ⁇ 0.05; ** :p ⁇ 0.01; *** :p ⁇ 0.001; t test).
- FIG. 7 Residual adhesion levels (percentages) of AIEC LF82 cells to T84 cells (preincubation protocol) in the presence of "soluble fraction b" (fraction 3), ⁇ -glucans (fraction 5), or ⁇ 6-glucans (fraction 4) from CNCM I-5268 yeast cell walls (means ⁇ wk; * : p ⁇ 0.05; *** : p ⁇ 0.001; t test).
- FIG. 8 Residual adhesion levels (percentages) of the AIEC LF82 strain to TC7/Caco-2 (preincubation protocol) in the presence of the "soluble fraction a" (fraction 1) obtained from the whole yeast strain CNCM I -3856 or yeast strain LV04, or "soluble fraction b" (fraction 3) obtained from whole yeast strain CNCM I-3856, or from yeast cell walls CNCM I-5268 (means ⁇ wk; ** :p ⁇ 0.01, *** :p ⁇ 0.001, t-test).
- FIG. 9 Levels of residual invasion (percentages) of TC7/Caco-2 cells by the bacterial strain AIEC LF82 (preincubation protocol) in the presence of the "soluble fraction b" (fraction 3) from yeast cell walls CNCM I- 5268.
- FIG. 10 Graph representing the protocol for administration of yeast fractions (FL: yeast fraction) in vivo in mice (murine model of colonization by AIEC). The yeast fractions are administered at a dose of 5 mg/mouse orally. Fractions tested: "soluble a" (fraction 1), obtained from the whole yeast strain CNCM I-3856 or "soluble b” (fraction 3), obtained from the whole yeast strain CNCM I-3856, or from CNCM I-5268 yeast cell walls.
- Fig. 11 Estimate of the number of AIEC LF82 bacteria in the faeces of mice 2 or 3 days after infection of the animals depending on the fraction of yeast administered. The results are given in number of AIEC bacteria/g of faeces (box and whiskers, min. to max.) (FP: parietal fraction).
- FIG. 12 Quantification of AIEC LF82 bacteria associated with the intestinal mucosa of mice treated or not, with yeast fractions, 4 days after infection. The results are given in number of AIEC bacteria/g of tissue (box and whiskers, min to max) (FP: parietal fraction).
- a temperature of about 100°C should be understood as a temperature between 80 and 120°C, in particular between 85 and 115°C, in particular between 90°C and 110°C and preferably between 95°C and 105°C.
- the inventors of the present application have developed a new process, making it possible to obtain a composition of parietal fragments of yeast, the effectiveness of which, in particular on the inhibition of adhesion and bacterial invasion, in particular of adherent and invasive E coli bacteria (AIEC), is significantly increased compared with whole yeasts or the derivatives described in the prior art.
- AIEC adherent and invasive E coli bacteria
- compositions of yeast polysaccharides extracted from parietal fragments of yeast exhibits an activity which inhibits adhesion and bacterial invasion which is much greater than compositions of yeast polysaccharides, the said polysaccharides of which are obtained from whole yeasts.
- compositions of yeast polysaccharide(s) according to the invention containing in particular ⁇ 1,6-glucans, and optionally mannans and ⁇ -glucans also exhibit a higher activity than the mannan fractions previously described.
- the present disclosure relates to a composition of yeast parietal polysaccharides comprising ⁇ -glucans.
- the ⁇ -glucans comprise ⁇ (1,6)-glucans (also called ⁇ 6-glucans below, in particular in the examples).
- said composition further comprises mannans and/or ⁇ -glucans.
- a yeast cell is schematically composed of an envelope, also called shell or wall, and a content.
- envelope also called shell or wall
- wall qualifying the polysaccharides or the yeast fragments described here are thus used synonymously.
- the term “parietal polysaccharides” thus means the polysaccharides constituting the wall (or the bark) of the yeast.
- yeast Three main groups of polysaccharides form the wall of yeast, in particular of Saccharomyces cerevisiae yeast: mannose polymers (or mannans), representing approximately 40% of the dry mass of the yeast wall, glucose polymers ( ⁇ - glucan and ⁇ -glucan), accounting for about 60% of the dry mass of the cell wall, and N-acetylglucosamine (chitin) polymers, accounting for about 2% of the dry mass of the cell wall.
- mannose polymers or mannans
- glucose polymers ⁇ - glucan and ⁇ -glucan
- chitin N-acetylglucosamine
- Glucans are polysaccharides composed of glucose monomers which may or may not be branched. They can be separated into different subtypes depending on the mode of glucose binding.
- ⁇ -glucans are polymers of glucose monomers mainly linked together by ⁇ (1-4) bonds.
- Yeast ⁇ -glucans are polysaccharides composed of glucose monomers and can be divided into two subtypes depending on the mode of glucose binding: long chains of approximately 1500 units of ⁇ -1,3-glucose which represent approximately 85% of yeast ⁇ -glucans, and the short chains of approximately 150 b-1,6-glucose units which represent approximately 15% of yeast ⁇ -glucans (Klis, F., Mol, P., Hellingwerf, K. and Brui, S. (2002) "Dynamic of cell wall structure in Saccharomyces cerevisiae", FEMS Microbiology Reviews 26, 239-256).
- the short b-1,6-glucan chains are involved in covalent bonds with ⁇ -1,3-glucan, mannoproteins and chitin. These cross-links may also contribute to the modular structure of the cell wall (Kollar, R et al. (1995) “Architecture of the yeast cell wall. b-(1,6)-glucan interconnects mannoprotein, b-(1,3 )-glucan, and chitin.” Journal of Biological Chemistry 270, 17762-17775).
- Mannans are polymers or oligomers of mannoses associated via an N-glycan type core.
- yeast Saccharomyces cerevisiae mannans are polymers of a1,6 mannoses branched at a1,2 with terminal a1,3 (see in particular Sendid et al., Med Sci (Paris). 2009; 25(5):473 -482).
- a fraction enriched in mannans according to the present application comprises at least 30% of mannans, in particular at least 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% mannans.
- ⁇ 6-glucan fraction is meant a fraction enriched in ⁇ -1,6-glucan polysaccharides.
- a fraction comprises at least 30% of b-1,6-glucans, in particular at least 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% , 90%, 95%, 99% b-1,6-glucan polymers.
- ⁇ 3-glucan fraction is meant a fraction enriched in ⁇ 1,3-glucans.
- a fraction comprises at least 30% of b-1,3-polymers glucan, in particular at least at least 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% of b-1 polymers ,3-glucan.
- a-glucan fraction (or glycogen) is understood to mean a fraction enriched in a1,4 a1,6 glucans.
- a fraction comprises at least 60% of a1,4 a1,6 glucan polymers, in particular at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% of a1,4 polymers -a1,6 glucans.
- the yeast polysaccharide compositions described in the prior art and typically obtained from whole yeast typically comprise from 60 to 80% ⁇ -glucans, conventionally from 65 to 75% ⁇ -glucans, from 5 to 25% ⁇ -glucans, typically 10 to 20% ⁇ -glucans and 5 to 25% mannans, typically 10 to 20% mannans.
- compositions obtained from parietal fraction(s) of yeast(s) are enriched in b-glucans, typically in b6 glucans, and preferably also in mannans.
- compositions obtained from a parietal fraction of yeast(s) comprise heterogeneous polymers associated by strong, non-dissociable and typically covalent bonds, composed of alpha-glucans , beta-glucans (in particular beta-6 glucans), and mannans, as described above.
- the yeast polysaccharide compositions of the invention typically comprise at least 30% of ⁇ -glucans, in particular from 30 to 50% of ⁇ -glucans, preferably from 35 to 45% of ⁇ -glucans, in particular of b(1,6)-glucans.
- the yeast polysaccharide compositions of the present disclosure further comprise mannans.
- the compositions of the present application are enriched in mannans and can comprise from 30 to 55% of mannans, in particular from 40 to 50% of mannans.
- compositions of yeast polysaccharides according to the present disclosure comprise ⁇ -glucans, in particular from 5 to 25%, in particular from 10 to 20% of ⁇ -glucans.
- said compositions comprise the following proportions of polysaccharides:
- ⁇ -glucans from 30 to 50% of ⁇ -glucans, preferably from 35 to 45% of ⁇ -glucans, in particular of b(1,6)-glucans
- the yeast walls (or shells) used in the present application may be derived from one or more types of yeast.
- Yeasts are unicellular eukaryotic microorganisms belonging to the kingdom of fungi.
- Yeasts particularly suitable for the implementation of the present disclosure are in particular yeasts of the Saccharomyces genus. These yeasts constitute a taxonomic genus of ascomycetes which do not form mycelium and include several species used in the food industry as fermentation agents.
- the yeasts belonging to the genus Saccharomyces can be chosen from food yeasts such as S. cerevisiae, S. uvarum, S. bayanus or S. pasteurianus.
- the yeast is a strain of the species Saccharomyces cerevisiae (brewery, or distillery, or bakery yeast, S. cerevisiae var. boulardii).
- Saccharomyces cerevisiae yeast strains deposited with the National Collection of Microorganism Cultures under the numbers CNCM I-3799, CNCM I-3856, CNCM I-4407, CNCM I-4563, CNCM 1-4812, CNCM I-4978, CNCM I-5128, CNCM I-5129, CNCM I-5268, and CNCM I-5269 are particularly well suited to the present disclosure.
- compositions of the present disclosure can be obtained from one or more yeasts of different strains, or of different species.
- compositions of the present disclosure are typically obtained from preparations of yeast walls or yeast wall fragments separated from the cellular contents (cytoplasm), in particular by extraction of parietal polysaccharides from yeast wall fragments. .
- the methods for obtaining yeast walls or yeast wall fragments are well known in the technical field of the present disclosure. In this regard, we can consult the reference work (“Yeast Technology”, 2nd edition, 1991, G Reed and TW Nagodawawithana, published by Van Nostrand Reinhold, New York, ISBN 0-444-31892-8).
- yeast wall fragments or yeast cell wall fragments can be obtained by chemical (solvents, acids, bases), physical (sonication, high pressure), enzymatic (typically use of proteases and nucleases) or autolysis (endogenous enzymes) of the yeast cells followed by separation of the soluble and insoluble parts, for example by physical means such as centrifugation and recovery of the insoluble fraction (or part).
- the centrifugation of the biomass of lysed yeast cells makes it possible to obtain a supernatant and a centrifugation pellet.
- the supernatant consists mainly of free amino acids and peptides resulting from the degradation of proteins and nucleotides resulting from the degradation of nucleic acids (RNA, DNA).
- the centrifugation pellet contains the intact or partially degraded yeast walls in the form of yeast cells emptied of their contents.
- Yeast autolysis is a hydrolysis of the cell content of the yeast by its own enzymes. It is typically obtained by placing a suspension of yeast cells under certain physical medium conditions and/or in contact with activators causing apoptosis of the yeast cells and the release of its enzymes into the cell body. Hydrolysis of cell contents produces soluble compounds.
- the insoluble fraction recovered after the separation step constitutes the product called cell walls, or walls of yeast and comprises the cytoskeleton of the yeasts and the membranes and components not solubilized by autolysis or heterolysis. This insoluble fraction is often recovered in the form of an aqueous suspension (or composition) of yeast cell wall.
- the yeast cell walls can be in liquid form (15-20% dry matter), in dry form (more than 85% dry matter) or in pasty form (25 to 85% dry matter).
- Yeast hulls are preferably presented in dry form.
- CNCM I-5268 yeast cell wall fragments are exemplified in the compositions and/or methods described herein.
- the present disclosure also relates to a process for obtaining a composition of parietal polysaccharides from yeast(s) as described above.
- said method comprises in particular:
- said method comprises a preliminary step, consisting in recovering a parietal fraction of yeast(s).
- this step is typically carried out by obtaining an insoluble fraction from a hydrolyzate (in particular an autolysate) of yeast(s), as described previously.
- This step aims in particular to eliminate all or part (at least 60%, in particular at least 75%, in particular at least 80%, at least 85%, at least 90% and more particularly at least 95%) of the compounds, not associated, or weakly associated with the wall (see in this regard the method for obtaining a yeast parietal fraction described previously).
- Step a) of hot extraction can be carried out by hot incubation of the yeast parietal fragments (s) in a solution, typically buffered at neutral pH, at a temperature above 75°C, in particular between 80 and 180°C, in particular between 90 and 150°C, in particular between 95 and 145°C. Typically at a temperature of about 120°C.
- neutral pH is meant a pH of approximately 7, in particular a pH of between 6 and 8.
- the hot incubation is typically maintained for a period of at least 30 minutes, in particular at least 1 h, typically between 1 h and 4 h, or between 1 h and 3 h. Preferably, the incubation is maintained for approximately 1.5 hours.
- the buffered solution is typically a solution based on citrate buffer (approximately 20 mM) or any other equivalent buffer solution in the field.
- the soluble and insoluble fractions are separated, typically by centrifugation, and the insoluble fraction (insoluble a) is recovered.
- the centrifugation can be carried out at a speed of 4000 to 6000 rpm, preferably approximately 5000 rpm for a duration of at least 20 min, in particular between 20 min and 40 min, preferably approximately 30 minutes. This step can be repeated between 2 and 4 times, preferably 2 times.
- the soluble fraction, recovered at the end of this hot hydrolysis step typically comprises phospho-peptidomannans, not strongly associated (typically associated non-covalently) with parietal polysaccharides.
- the method preferably comprises a step a1) of extraction in a strong base solution of an insoluble fraction, typically a step of incubation of the insoluble fraction obtained at the end of step a) (known as "insoluble fraction a") in a strong base solution, after which the insoluble fraction (called “insoluble fraction a1" is recovered.
- insoluble fraction a1 the fraction (or composition) incubated in the solution weak acid of step b) described above is then the “insoluble fraction a1”.
- Step a1), of extraction in a strong base solution typically comprises a step of incubating the insoluble fraction a) in a strong base solution.
- the strong base solution is typically a solution of sodium hydroxide (NaOH) or any other equivalent, preferably concentrated to about 1 N.
- Incubation in the strong base solution is typically carried out at room temperature, preferably between 16 and 24°C, especially at about 20°C. It is ideally carried out with stirring for a period of at least 16 hours, typically between 4 p.m. and 32 p.m. and preferably 24 hours.
- the soluble and insoluble fractions are then separated, typically by centrifugation, and the insoluble fraction a1) is recovered.
- the centrifugation can be carried out at a speed of 5000 to 8000 rpm, preferably approximately 7000 rpm for a duration of at least 20 min, in particular between 20 min and 40 min, preferably approximately 30 minutes. Steps hot incubation followed by centrifugation. The inventors believe that this step makes it possible to eliminate residual phospho-peptidomannans.
- Step b) of extraction in a weak acid solution typically comprises a step of incubation of the "insoluble fraction a" or "a1" (if the intermediate extraction step in a strong base has implemented) in a weak acid solution.
- the weak acid solution is typically a solution of acetic acid or any other equivalent, preferably concentrated to around 0.5 N.
- Incubation in the weak acid solution is typically carried out at a temperature of at least 70° C, in particular between 75 and 130, in particular between 75 and 115°C, in particular at about 90°C. It is ideally carried out, preferably with stirring, for a period of at least 1 hour, typically between 2 and 4 hours and preferably 3 hours.
- the soluble and insoluble fractions are then separated, preferably by centrifugation, and the soluble fraction (called soluble fraction b) is recovered.
- the centrifugation can be carried out at a speed of 4000 to 6000 rpm, preferably approximately 5000 rpm for a duration of at least 20 min, in particular between 20 min and 40 min, preferably approximately 30 minutes. This step must be repeated at least twice, in particular at least 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, in particular between 3 and 8 times.
- centrifugation steps of the method of the present application are carried out at room temperature, preferably between 16 and 24°C, in particular at around 20°C.
- the “soluble b” fraction obtained according to the protocol described here is a fraction enriched in ⁇ -glucans, in particular in b-6 glucans and preferably also in mannans (as defined previously). Such a fraction also typically contains ⁇ -glucans.
- the process of the invention makes it possible to obtain a composition in particular as described previously, and having the advantageous effects as claimed here.
- a fraction of ⁇ 3-glucan ie., typically enriched in beta-3 glucans as described above
- the insoluble fraction also called “insoluble fraction b”
- this step b) can be repeated at least twice, in particular at least 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, in particular between 3 and 8 times.
- a fraction enriched with ⁇ 6-glucans can be obtained from the soluble fraction obtained at the end of step (b) (“soluble fraction b”).
- soluble fraction b an isolated fraction of ⁇ 6-glucans can for example be obtained by enzymatic treatment, typically with an amyloglucosidase (for example from Aspergillus niger).
- the soluble fraction obtained at the end of step (b) (“soluble fraction b”) can be treated with an iodine solution (as illustrated in the examples).
- Incubation in the iodine solution is typically carried out at room temperature (preferably between 16 and 24°C, in particular at approximately 20°C) (it is ideally carried out with stirring for a period of at least 15 min, typically between 20 and 45 min, and preferably 30 min).
- the soluble and insoluble fractions are then separated, typically by centrifugation, and the soluble fraction (also called “soluble fraction c”) recovered.
- the centrifugation can be carried out at a speed of 4000 to 6000 rpm, preferably approximately 5000 rpm for a duration of at least 20 min, in particular between 20 min and 40 min, preferably approximately 30 minutes.
- ethanol solution can then be added to the supernatant and the solution centrifuged under the same conditions as before).
- a concentrated solution of strong acid typically a hydrochloric acid solution concentrated to at least 2N, preferably to approximately 3N
- This second method makes it possible to recover isolated ⁇ 6-glucan and ⁇ -glucan enriched fractions (see also the methods described in the results).
- the data obtained by the inventors have shown that the "soluble b" fraction, obtained from yeast cell walls, very significantly inhibits the adhesion of pathogenic bacteria of the type AIEC, with the consequence of a significant reduction in the invasion of AIEC bacteria (adherent invasive E. coli) in the intestinal tissues and therefore in their infectivity.
- AIEC have also been shown to adhere to intestinal cells by binding to a mannose-rich glycoprotein known as CEACAM6.
- CEACAM6 mannose-rich glycoprotein
- transgenic mice expressing the human CEACAM6 protein become very susceptible to AIEC infections whereas this pathotype is generally not very virulent against rodents. Treatment of mice infected with yeast strains or identified yeast derivatives reduced the colonization of the digestive tract by AIEC bacteria, thus validating the in vitro data.
- the “soluble fraction b”, as described here, comprises alpha (1-4) and (1-6) glucosidic units as well as mannosidic units which seem important for the presentation or the 3D conformation of the binding structures, so that such a fraction makes it possible to effectively inhibit the adhesion of bacteria to the intestinal wall.
- compositions having an advantageous activity as described here, and/or obtained according to the method of the present disclosure as a medicament.
- a composition as described here is particularly suitable for the treatment or prevention of gastrointestinal pathologies or diseases.
- Said composition is typically a composition obtained from yeast cell walls, preferably of the genus Saccharomyces and enriched in b glucans (in particular b6 glucans) and advantageously also in mannans.
- said composition comprises at least 30% ⁇ -glucans and advantageously at least 30% mannans.
- treatment are defined as the administration of a composition as described herein to a patient in need thereof, for the purpose of curing, relieving , to remedy, ameliorate, and/or affect disease, and/or any symptoms of disease, including gastrointestinal disease, bowel disorder, or functional bowel disorder.
- treating means the reduction or alleviation of at least one undesirable clinical symptom associated with the disease, for example pain, inflammation, diarrhea, nausea or vomiting, loss appetite, or fatigue.
- prevent or "prevention” as used herein are defined as the administration of a composition as described herein to a patient in need thereof, for the purpose of preventing the onset of disease or at least one of his symptoms and/or to reduce the severity of at least one of his symptoms.
- compositions of the invention can be used in clinical nutrition for the treatment or prevention of the pathologies described herein.
- patient is typically meant a mammal and in particular a human being.
- the patient may be in remission and the administration of a composition according to the present application may aim to avoid or limit relapses, in particular to reduce the severity of at least one of the symptoms of the disease or of the functional disorder in case of relapse.
- the composition of the invention is intended for veterinary use, typically for animal health.
- the patient is a non-human mammal, typically chosen from domestic or companion animals (such as cats or dogs) or livestock (ruminants, pigs, goats, sheep, horses, donkeys, etc. ).
- the gastrointestinal pathologies covered by the present application may or may not be chronic, possibly associated, or not, with diarrhea or constipation. They typically include functional bowel disorders, infectious bowel disease, colorectal cancer and/or chronic inflammatory bowel disease.
- Functional bowel disorders include in particular irritable bowel syndrome, functional abdominal distension, functional constipation, functional diarrhea, and any other unspecified functional bowel disorder (see in particular P. de Saussure & D Bertolini; Rev Med Switzerland 2006; volume 2.31649, “Functional intestinal disorders: contributions and limits of evidence-based medicine”.
- Infectious intestinal diseases typically include gastroenteritis, food poisoning and/or diarrhoea, of viral, bacterial or parasitic origin.
- Inflammatory bowel disease (IBD) typically includes Crohn's disease and ulcerative colitis.
- compositions of the present application are particularly useful for combating gastrointestinal colonization by pathogenic microorganisms, reducing adhesion to the intestinal mucosa, or even reinforcing the barrier function of the intestine against pathogenic microorganisms.
- Tests for inhibiting the adhesion of pathogenic microorganisms on intestinal epithelial cultures such as the T84 line, or on enterocytes obtained from intestinal biopsies of patients, with or without preincubation with the composition tested are in particular described in the results of the present application as well as in application WO 2009/103884 and the article by Sivignon et al. (IBD, 2015, vol 21 (2):276-286).
- infectious gastrointestinal pathologies but also IBD and colorectal cancer are generally associated with the presence of pathogenic microorganisms and/or an imbalance of the intestinal microbiota (dysbiosis) linked to the invasive nature of a specific pathogenic microorganism (see Rahmouni O, Dubuquoy L, Desreumaux P, Neut C. “Enteric microflora in inflammatory bowel disease patients”. Med Sci (Paris). 2016 Nov;32(11):968-973; Kaper J. B., Nataro J. P. , Mobley H.L.
- compositions described here are particularly useful for reducing the adhesion and invasion of the gastric and/or intestinal mucous membranes and the associated inflammation, in particular for the pathologies listed above.
- the target pathogenic microorganisms of the compositions described here are typically intestinal pathogens, typically bacterial species of the Enterobacteriaceae family (such as Salmonella spp., Klebsiella spp., Serratia spp. or Escherichia coli (E. coli), bacteria of the Clostridioides difficile species or even yeasts of the Candida albicans species, advantageously bacteria whose adhesion to cells involves the adhesin FimH of type 1 pili.E. coli bacteria associated with the colonic mucosa (mucosa associated E. coli) are preferably targeted, and in particular E. coli bacteria of the AIEC type (E coli), ETEC (enterotoxigenic E.
- Ectal cancer or at risk of developing for colorectal cancer.
- the present application also relates to the non-therapeutic use of a composition as described above in the form of a functional food, a food supplement or a functional food aimed at improving or maintaining intestinal comfort, and/ or to improve the intestinal flora (typically by limiting intestinal colonization by pathogenic commensal bacteria).
- improving or maintaining intestinal comfort is meant in particular limiting or preventing intestinal bloating, limiting or preventing aerophagia, and/or regulating transit in humans or animals.
- a composition according to the present application may comprise, in addition to the active fraction extracted from yeast cell walls (consisting of the parietal polysaccharide fraction as described above and preferably obtained according to the process described), any excipient, support and / or adjuvant conventionally used in the pharmaceutical field, or for the formulation of a food supplement, nutraceutical, or functional food, and which is chemically compatible with said active fraction (ie ⁇ -glucans, mannans and ⁇ -glucans parietal yeast, in particular the “soluble fraction b” illustrated as an example).
- a composition of the invention may comprise constituents chosen from vitamins, trace elements, amino acids, and other additives intended for food and/or animal or human health.
- a food which contains ingredients having beneficial effects for health or capable of improving physiological functions, in particular for the present, digestive well-being.
- Food supplement means a foodstuff intended to supplement the normal diet, in accordance with Directive 2002/46/EC.
- a food supplement constitutes a concentrated source of nutrients or other substances having a nutritional or physiological effect, when taken alone or in combination, in small quantities.
- foodstuffs intended for particular nutrition we mean a food with a particular nutritional objective, intended for a well-defined population group, such as infants, young children, athletes.
- Physiologically acceptable adjuvants, vehicles and excipients are typically described in the "Handbook of Pharmaceutical Excipients", second edition, American Pharmaceutical Association, 1994.
- Carriers, excipients, and adjuvants conventionally used include, but are not limited to, saline solutions, solvents, dispersing media, coatings, preservatives, antibacterial and antifungal agents, isotonic agents, and absorption-delaying agents.
- composition can be used as a medicament or as an active ingredient, or else in the context of a non-therapeutic use as, typically, a food supplement.
- the formulation and the dosage of the active fraction are then adapted to the chosen use.
- composition in the context of a therapeutic use, can be formulated for oral or enteral administration.
- the composition of the food according to the present invention may be in different galenic forms, such as the liquid form or in the form of a capsule, dragee, pill, powder, suppository, or any other galenic formulation.
- the food composition according to the present invention can be presented in a large number of food and drink forms, for example juices or milk-based preparations.
- step 3 at least 5 times until 5L of supernatant has been collected (consisting mainly of glycogen and bq-Glucans, also called “soluble fraction b”). Neutralize the supernatant with a solution of NaOH, concentrated by water evaporator. Then dialyze (MWCO 3500) against water at 4°C, overnight. The fraction obtained constitutes the soluble fraction b). Analysis of this fraction demonstrates that it comprises b-6 glucans, ⁇ -glucans (glycogen) and mannans strongly bound (ie not dissociated by the hot extraction step) to the glucan polymers.
- CNCM I-3856 live yeast Saccharomyces cerevisiae deposited under the number CNCM I-3856;
- Adhesion test The tests were carried out on T84 or Caco-2/TC7 cells seeded at 1.5x10 5 cells/well in a 48-well plate and incubated for 48 hours at 37°C in an atmosphere containing 5% of C02.
- the AIEC LF82 bacteria at 1.2 ⁇ 10 7 CFU/mL were incubated for 1 hour, on a Stuart® orbital shaker at room temperature, with increasing concentrations of the yeast sample (ratio 1:1).
- the cells were infected with the bacteria/yeast extract mixture for 3 hours at 37° C. in an atmosphere containing 5% C02. Cells were infected at a multiplicity of infection of 10 bacteria/cell.
- Mean adhesion rates (from at least 3 independent experiments) were expressed as percent residual adhesion, which is the ratio of bacterial adhesion in the presence of yeast to adhesion in l absence of yeast is considered 100%.
- the error bars correspond to the standard error of the mean or SEM.
- Invasion test the protocol is identical to that of the adhesion test, however after the 3 hour incubation period, the cells are incubated for 1 hour with gentamycin (100 ⁇ g/mL), so as to eliminate the extracellular bacteria and counting only invasive bacteria.
- the “soluble a” fraction (phospho-peptidomannan) obtained from whole CNCM I-3856 yeasts significantly inhibits the adhesion of AIEC bacteria to T84 epithelial cells.
- the “soluble b” fraction derived from this same whole yeast also exhibits a significant inhibitory activity on the adhesion of AIEC bacteria.
- FIG. 4 shows that the phosphorylated ⁇ 3-glucan fraction, derived from whole CNCM I-3856 yeast also significantly, although more moderately, inhibits the adhesion of AIEC bacteria to T84 epithelial cells.
- FIG. 5 illustrates the comparison of the inhibitory activities on the adhesion of AIEC bacteria to T84 epithelial cells, of “soluble b” fractions obtained either from whole yeasts (CNCM I-3856), or from fraction parietal of this same yeast. Although both exhibit significant inhibitory activity, the fraction obtained from the parietal fraction exhibits greater activity than that obtained from whole yeast (residual adhesions at a dose of 1 mg/mL is 17% and 42 % respectively). These different activities are correlated with different compositions of the “soluble b” fraction.
- FIG. 6 illustrates the comparison of the inhibitory activities on the adhesion of AIEC bacteria to T84 epithelial cells, of the soluble fractions b) obtained from two yeast parietal fractions: CNCM I-5268 or CNCM I-3856. A very significant inhibitory activity is observed for these two fractions. The percentages of residual adhesion for equal doses being of the same order, this result strongly suggests that the increase in inhibitory activity is not directly linked to the strain used (CNCM I-5268 vs. CNCM I-3856 ) but rather to the process of obtaining.
- the soluble fractions b) obtained from parietal yeast fractions exhibit an inhibitory activity, on the adhesion of AIEC bacteria to epithelial cells, which is much greater than that observed for the soluble fractions b) obtained from whole yeasts.
- FIG. 7 illustrates the residual adhesion of AIEC LF82 bacteria to T84 epithelial cells, in the presence of soluble fractions b), glycogen or bq-glucans, obtained from parietal fractions of CNCM I-5268 yeasts.
- the results show that the bq-glucans are less effective than the soluble fraction b) and that the glycogen fraction has an intermediate activity.
- the soluble fraction b) is the most effective fraction.
- Figure 8 shows the residual adhesion (in percentage) of AIEC LF82 bacteria to TC7/Caco-2 cells in the presence of mannan fractions (growinging mannans) obtained from whole yeast (CNCM I-3856, or LV04), soluble b) obtained from whole CNCM I-3856 yeast or from the parietal fraction of CNCM I-5268 yeast.
- FIG. 9 illustrates results showing a strong inhibition of the invasion of TC7/Caco-2 cells by AIEC LF82 bacteria pre-incubated with increasing doses of the soluble fraction b) obtained from parietal fractions of yeasts CNCM I-5268.
- the colonization of the intestinal tract by the AIEC LF82 strain was carried out in CEABAC10 transgenic mice expressing the human protein CEACAM6, acting as a receptor for AIEC bacteria in the context of Crohn's disease.
- the yeast fractions were administered orally once a day from day -7 to day 0 and twice a day (5 hours apart) from day 1 to day 3.
- the fractions were solubilized in PBS at a concentration of 25 mg/ml (every day) and an amount of 0.2 ml/mouse was administered by gavage (5 mg/mouse).
- mice received 0.5% DSS in water of drink.
- the mice were treated po with streptomycin (5 mg/mouse).
- LB culture medium Lia Bertani
- AIEC LF82 bacteria strain was inoculated (to 1/100th) with the AIEC LF82 bacteria strain and incubated at 37° C. with stirring until the exponential growth phase. After centrifugation, the bacteria were concentrated at 2.5 ⁇ 10 10 bacteria/mL. A quantity of 0.2 ml_ was then administered by gavage to the mice, ie 5 ⁇ 10 9 bacteria/ml.
- mice were monitored for 4 days following the infection. Feces were collected on days 1, 2, 3 and 4 after infection to assess bacterial colonization.
- mice were euthanized on the fourth day after the infection and the intestine was removed to evaluate the bacterial colonization associated with the mucosa (ileum+colon).
- Figure 11 shows the estimate of the number of bacteria in the faeces of mice 2 and 3 days post-infection, depending on the fraction of yeast administered. The results show that the quantity of bacteria in the faeces is reduced by 25 in response to the treatment with the soluble fraction b) obtained from parietal fraction of yeast CNCM I-5268 compared to the untreated group, which confirms the excellent properties anti-adhesive properties of this fraction demonstrated in vitro in a pre-clinical model.
- FIG. 12 shows the quantification of the AIEC LF82 bacteria associated with the intestinal mucosa in mice treated or not with the yeast fractions, 4 days after infection.
- the results indicate the absence of bacteria in 100% mice treated with the soluble fraction b) obtained from parietal fraction of yeast CNCM 1-5268, thus corroborating the results obtained in the faeces.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22713713.0A EP4308138A1 (fr) | 2021-03-16 | 2022-03-15 | Inhibiteurs glycosidiques de levure |
AU2022237933A AU2022237933A1 (en) | 2021-03-16 | 2022-03-15 | Glycoside inhibitors of yeast |
JP2023554878A JP2024512375A (ja) | 2021-03-16 | 2022-03-15 | 酵母のグリコシド阻害剤 |
US18/550,349 US20240148778A1 (en) | 2021-03-16 | 2022-03-15 | Glycoside inhibitors of yeast |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR2102618 | 2021-03-16 | ||
FR2102618A FR3120789B1 (fr) | 2021-03-16 | 2021-03-16 | Inhibiteurs glycosidiques de levure |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022195212A1 true WO2022195212A1 (fr) | 2022-09-22 |
Family
ID=76730653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2022/050459 WO2022195212A1 (fr) | 2021-03-16 | 2022-03-15 | Inhibiteurs glycosidiques de levure |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240148778A1 (fr) |
EP (1) | EP4308138A1 (fr) |
JP (1) | JP2024512375A (fr) |
AU (1) | AU2022237933A1 (fr) |
FR (1) | FR3120789B1 (fr) |
WO (1) | WO2022195212A1 (fr) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006021965A1 (fr) | 2004-08-23 | 2006-03-02 | Bharat Biotech International Limited | Formulations synergistiques eucaryotes pour troubles gastro-intestinaux |
WO2009103884A2 (fr) | 2007-12-26 | 2009-08-27 | Lesaffre Et Compagnie | Composition pour l'alimentation humaine et/ou animale, ses utilisations, levures |
US20090214562A1 (en) * | 2005-05-03 | 2009-08-27 | Karel Steven J | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection |
FR2928652A1 (fr) | 2008-03-12 | 2009-09-18 | Lesaffre Et Compangie Sa | Composition pour l'alimentation humaine et/ou animale,ses utilisations,levures |
WO2020079641A1 (fr) * | 2018-10-17 | 2020-04-23 | Pegaso S.R.L. | Compositions comprenant des huiles essentielles et/ou des hydrolates provenant de plantes d'origine italienne et leur utilisation pour le traitement de troubles gastro-intestinaux et génito-urinaires |
FR3089788A1 (fr) * | 2018-12-17 | 2020-06-19 | Lesaffre Et Compagnie | Souche de levure Saccharomyces cerevisiae pour le traitement et/ou la prévention de candidoses oropharyngées |
-
2021
- 2021-03-16 FR FR2102618A patent/FR3120789B1/fr active Active
-
2022
- 2022-03-15 JP JP2023554878A patent/JP2024512375A/ja active Pending
- 2022-03-15 AU AU2022237933A patent/AU2022237933A1/en active Pending
- 2022-03-15 US US18/550,349 patent/US20240148778A1/en active Pending
- 2022-03-15 WO PCT/FR2022/050459 patent/WO2022195212A1/fr active Application Filing
- 2022-03-15 EP EP22713713.0A patent/EP4308138A1/fr active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006021965A1 (fr) | 2004-08-23 | 2006-03-02 | Bharat Biotech International Limited | Formulations synergistiques eucaryotes pour troubles gastro-intestinaux |
US20090214562A1 (en) * | 2005-05-03 | 2009-08-27 | Karel Steven J | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection |
WO2009103884A2 (fr) | 2007-12-26 | 2009-08-27 | Lesaffre Et Compagnie | Composition pour l'alimentation humaine et/ou animale, ses utilisations, levures |
FR2928652A1 (fr) | 2008-03-12 | 2009-09-18 | Lesaffre Et Compangie Sa | Composition pour l'alimentation humaine et/ou animale,ses utilisations,levures |
WO2020079641A1 (fr) * | 2018-10-17 | 2020-04-23 | Pegaso S.R.L. | Compositions comprenant des huiles essentielles et/ou des hydrolates provenant de plantes d'origine italienne et leur utilisation pour le traitement de troubles gastro-intestinaux et génito-urinaires |
FR3089788A1 (fr) * | 2018-12-17 | 2020-06-19 | Lesaffre Et Compagnie | Souche de levure Saccharomyces cerevisiae pour le traitement et/ou la prévention de candidoses oropharyngées |
Non-Patent Citations (23)
Title |
---|
"Handbook of Pharmaceutical Excipients", 1994, AMERICAN PHARMACEUTICAL ASSOCIATION |
"Joint FAO/WHO Expert Consultation Probiotics in food", FAO FOOD AND NUTRITION PAPER NR85, ISBN: 92-5-105513-0 |
"Method for Fingerprinting Yeast Cell Wall Mannan", JOURNAL OF BACTERIOLOGY, vol. 100, 1969, pages 1175 |
"Méthodologies of tissue préservation and analysis of the glycogen content of the Broiler chicken liver", POULTRY SCIENCE, vol. 86, 2007, pages 2653 |
"Refinement of the structures of cell-wall glucan of Schizosaccharomyces pombe by chemical modification and NMR spectroscopy", CARBOHYDRATE RES., vol. 339, 2004, pages 2255 |
"The structure of b(1->3)-D-glucan from yeast cell walls", BIOCHEM J, vol. 135, 1973, pages 19 |
BARNICH ET AL., JCI, 2007 |
CUEVAS-RAMOS G ET AL.: "Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells", PNAS. USA, vol. 107, 2010, pages 11537 - 11542, XP055063641, DOI: 10.1073/pnas.1001261107 |
ENFIN, PENGKUMSRI ET AL., FOOD SCI TECHNOL, CAMPINAS, vol. 31, no. 1, 2017, pages 124 - 130 |
G REEDT.W. NAGODAWAWITHANA: "Yeast Technology", 1991, VAN NOSTRAND REINHOLD |
GIBSONM ALUGONGO ET AL: "Review: Utilization of yeast of origin in artificially raised calves", JOURNAL OF ANIMAL SCIENCE AND BIOTECHNOLOGY, BIOMED CENTRAL LTD, LONDON, UK, vol. 8, no. 1, 1 May 2017 (2017-05-01), pages 1 - 12, XP021244599, DOI: 10.1186/S40104-017-0165-5 * |
JAWAHARA ET AL., PLOS ONE, vol. 7, no. 7, 2012, pages e40648 |
KAPER J.B.NATARO J.P.MOBLEY H.L., PATHOGENIC ESCHERICHIA |
KAPER J.B.NATARO J.P.MOBLEY H.L: "Pathogenic Escherichia coli", NATURE REVIEW MICROBIOLOGY, vol. 2, 2004, pages 123 - 140 |
KLIS, F.MOL, P.HELLINGWERF, K.BRUI, S.: "Dynamic of cell wall structure in Saccharomyces cerevisiae", FEMS MICROBIOLOGY REVIEWS, vol. 26, 2002, pages 239 - 256, XP009080890, DOI: 10.1111/j.1574-6976.2002.tb00613.x |
KOLLAR, R ET AL.: "Architecture of the yeast cell wall. 13-(1,6)-glucan interconnects mannoprotein, (3-(1,3)-glucan, and chitin", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, 1995, pages 17762 - 17775 |
P. DE SAUSSURED BERTOLINI: "Troubles fonctionnels intestinaux : apports et limites de la médecine basée sur les preuves", REV MED SUISSE, vol. 2, 2006, pages 31649 |
RAHMOUNI ODUBUQUOY LDESREUMAUX PNEUT C.: "Enteric microflora in inflammatory bowel disease patients", MED SCI (PARIS, vol. 32, no. 11, November 2016 (2016-11-01), pages 968 - 973 |
ROUSSEL C ET AL: "Anti-infectious properties of the probiotic Saccharomyces cerevisiae CNCM I-3856 on enterotoxigenic E.coli (ETEC) strain H10407", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 102, no. 14, 25 May 2018 (2018-05-25), pages 6175 - 6189, XP036531450, ISSN: 0175-7598, [retrieved on 20180525], DOI: 10.1007/S00253-018-9053-Y * |
SAMUELSEN A B ET AL: "Effects of orally administered yeast-derived beta-glucans: A review", MOLECULAR NUTRITION & FOOD RESEARCH, WILEY - VCH VERLAG, WEINHEIM, DE, vol. 58, no. 1, 1 January 2014 (2014-01-01), pages 183 - 193, XP002733985, ISSN: 1613-4125, [retrieved on 20130910], DOI: 10.1002/MNFR.201300338 * |
SENDID ET AL., MED SCI (PARIS)., vol. 25, no. 5, 2009, pages 473 - 482 |
SIVIGNON ET AL., IBD, vol. 21, no. 2, 2015, pages 276 - 286 |
SIVIGNON ET AL., INFLAMM BOWEL DIS, vol. 21, no. 2, 2015, pages 276 - 286 |
Also Published As
Publication number | Publication date |
---|---|
US20240148778A1 (en) | 2024-05-09 |
FR3120789B1 (fr) | 2024-01-19 |
JP2024512375A (ja) | 2024-03-19 |
EP4308138A1 (fr) | 2024-01-24 |
AU2022237933A1 (en) | 2023-09-21 |
FR3120789A1 (fr) | 2022-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102345546B1 (ko) | 소화 건강, 체중 조절, 면역 강화 및 건강 개선을 위한 다중섬유 프리바이오틱 제제 | |
EP2306847B1 (fr) | Composition de maltodextrines branchees et d'organismes eucaryotes dotes d'une paroi polysaccharidique utilisees dans le domaine du bien etre. | |
JP2023052414A (ja) | 免疫機能を調節するため及び腸の炎症を治療するためのベータ-1,3-グルカンの使用 | |
Miranda-Nantes et al. | Hypoglycemic and hypocholesterolemic effects of botryosphaeran from Botryosphaeria rhodina MAMB-05 in diabetes-induced and hyperlipidemia conditions in rats | |
EP2931289B1 (fr) | Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses | |
FR2853908A1 (fr) | Produit immunomodulateur obtenu a partir d'une culture de bifidobacterium et compositions le contenant | |
CN106103696A (zh) | 新颖的拟干酪乳杆菌菌株 | |
CN106820151A (zh) | 一种双壳复合保健组合物、制备方法及应用 | |
TW202027757A (zh) | 免疫刺激劑及感染預防方法 | |
EP2919592B1 (fr) | Utilisation de maltodextrines branchees dans le bien-etre intestinal du nourrisson | |
EP4308138A1 (fr) | Inhibiteurs glycosidiques de levure | |
JP4054697B2 (ja) | 便秘改善剤 | |
KR101952991B1 (ko) | 맥주 생산으로부터 생성되는 바이오매스로부터 얻은 지방 결합제 | |
KR20110132887A (ko) | 간, 위 기능 및 숙취 개선용 조성물 | |
CN113924107B (zh) | 用于预防单纯性和/或复发性膀胱炎的包含酵母的组合物 | |
BE1028330B1 (fr) | Composition comprenant de l'Akkermansia muciniphila et de l'extrait de camu camu | |
JP2006241020A (ja) | 免疫系賦活剤 | |
FR2974512A1 (fr) | Composition anti-inflammatoire de l'intestin comprenant du maltitol | |
JP2004107281A (ja) | 酵母細胞壁を有効成分とする消化管免疫賦活剤および飲食品 | |
WO2023036957A1 (fr) | Utilisation de faecalibacterium pour traiter une infection par un virus respiratoire | |
FR3078610A1 (fr) | Composition de probiotiques particuliers et utilisation pour diminuer les symptomes inflammatoires digestifs | |
JP2010275248A (ja) | ユーグレナ加工物の製造方法、ユーグレナ加工物及びプリン体吸収抑制組成物 | |
FR3078609A1 (fr) | Composition pour diminuer la sensibilite au gluten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22713713 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023554878 Country of ref document: JP Ref document number: 2022237933 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18550349 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2022237933 Country of ref document: AU Date of ref document: 20220315 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022713713 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022713713 Country of ref document: EP Effective date: 20231016 |